Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

doi:10.1016/j.echo.2020.02.005

Randomized Controlled Trial

. 2020 May;33(5):644-646.

doi: 10.1016/j.echo.2020.02.005. Epub 2020 Mar 18.

Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

Karan Bami¹, Sumeet Gandhi², Howard Leong-Poi¹, Andrew T Yan¹, Edwin Ho³, Mohammed Zahrani¹, Vinay Garg⁴, Fei Zuo⁵, Hwee Teoh⁶, Adrian Quan⁷, Lawrence A Leiter⁸, Richard E Gilbert⁸, Bernard Zinman⁹, Kevin E Thorpe⁵, Peter Jüni⁵, C David Mazer¹⁰, Subodh Verma⁷, Geraldine Ong¹, Kim A Connelly¹¹

Affiliations

¹ Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada.
² Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada; Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada.
³ Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada; Division of Cardiology, Montefiore Medical Center, Bronx, New York.
⁴ Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada; Division of Cardiac Surgery, St. Michael's Hospital, Toronto, Ontario, Canada.
⁵ Applied Health Research Centre, St. Michael's Hospital, Toronto, Ontario, Canada.
⁶ Division of Cardiac Surgery, St. Michael's Hospital, Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, Ontario, Canada.
⁷ Division of Cardiac Surgery, St. Michael's Hospital, Toronto, Ontario, Canada.
⁸ Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, Ontario, Canada.
⁹ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
¹⁰ Department of Anesthesia, St. Michael's Hospital, Toronto, Ontario, Canada.
¹¹ Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada; Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.

PMID: 32199780
DOI: 10.1016/j.echo.2020.02.005

Randomized Controlled Trial

Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

Karan Bami et al. J Am Soc Echocardiogr. 2020 May.

. 2020 May;33(5):644-646.

doi: 10.1016/j.echo.2020.02.005. Epub 2020 Mar 18.

Authors

Affiliations

¹ Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada.
² Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada; Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada.
³ Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada; Division of Cardiology, Montefiore Medical Center, Bronx, New York.
⁴ Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada; Division of Cardiac Surgery, St. Michael's Hospital, Toronto, Ontario, Canada.
⁵ Applied Health Research Centre, St. Michael's Hospital, Toronto, Ontario, Canada.
⁶ Division of Cardiac Surgery, St. Michael's Hospital, Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, Ontario, Canada.
⁷ Division of Cardiac Surgery, St. Michael's Hospital, Toronto, Ontario, Canada.
⁸ Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, Ontario, Canada.
⁹ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
¹⁰ Department of Anesthesia, St. Michael's Hospital, Toronto, Ontario, Canada.
¹¹ Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada; Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.

PMID: 32199780
DOI: 10.1016/j.echo.2020.02.005

No abstract available

PubMed Disclaimer

Cited by

Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.
Pourafkari M, Connelly KA, Verma S, Mazer CD, Teoh H, Quan A, Goodman SG, Rai A, Ng MY, Deva DP, Triverio P, Jiminez-Juan L, Yan AT, Ge Y. Pourafkari M, et al. Cardiovasc Diabetol. 2024 Aug 28;23(1):319. doi: 10.1186/s12933-024-02344-6. Cardiovasc Diabetol. 2024. PMID: 39198860 Free PMC article. Clinical Trial.
Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial.
Ovchinnikov A, Potekhina A, Filatova A, Svirida O, Zherebchikova K, Ageev F, Belyavskiy E. Ovchinnikov A, et al. Cardiovasc Diabetol. 2025 May 9;24(1):196. doi: 10.1186/s12933-025-02756-y. Cardiovasc Diabetol. 2025. PMID: 40346546 Free PMC article. Clinical Trial.
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.
Inciardi RM, Pagnesi M, Lombardi CM, Anker SD, Cleland JG, Dickstein K, Filippatos GS, Lang CC, Ng LL, Pellicori P, Ponikowski P, Samani NJ, Zannad F, van Veldhuisen DJ, Solomon SD, Voors AA, Metra M. Inciardi RM, et al. Eur J Heart Fail. 2022 Nov;24(11):2131-2139. doi: 10.1002/ejhf.2593. Epub 2022 Jul 12. Eur J Heart Fail. 2022. PMID: 35748048 Free PMC article.
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS. Kanie T, et al. Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650. doi: 10.1002/14651858.CD013650.pub2. Cochrane Database Syst Rev. 2021. PMID: 34693515 Free PMC article.
Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.
Rai A, Connelly KA, Verma S, Mazer CD, Teoh H, Ng MY, Roifman I, Quan A, Pourafkari M, Jimenez-Juan L, Ramanan V, Ge Y, Deva DP, Yan AT. Rai A, et al. Acta Diabetol. 2022 Apr;59(4):575-578. doi: 10.1007/s00592-021-01823-6. Epub 2022 Jan 21. Acta Diabetol. 2022. PMID: 35061101 Clinical Trial. No abstract available.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

Affiliations

Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

Authors

Affiliations

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical